JPMORGAN ASSET MANAGEMENT (CHINA) C SID MORGAN INNOVATIVE PHARMACEUTICAL IND
No trades
Key stats
About JPMORGAN ASSET MANAGEMENT (CHINA) C SID MORGAN INNOVATIVE PHARMACEUTICAL IND
Home page
Inception date
May 9, 2022
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
JPMorgan Asset Management (China) Co Ltd.
ISIN
CNE100005B86
Closely tracks the underlying index, and pursues the minimization of tracking deviation and tracking err.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks98.82%
Health Technology98.21%
Commercial Services0.61%
Bonds, Cash & Other1.18%
Cash1.18%
Stock breakdown by region
Asia97.79%
Europe2.21%
North America0.00%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
560900 invests in stocks. The fund's major sectors are Health Technology, with 98.21% stocks, and Commercial Services, with 0.61% of the basket. The assets are mostly located in the Asia region.
560900 top holdings are WuXi AppTec Co., Ltd. Class A and Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A, occupying 9.99% and 9.96% of the portfolio correspondingly.
No, 560900 doesn't pay dividends to its holders.
560900 shares are issued by JPMorgan Chase & Co. under the brand CIFM. The ETF was launched on May 9, 2022, and its management style is Passive.
560900 expense ratio is 0.40% meaning you'd have to pay 0.40% of your investment to help manage the fund.
560900 follows the CSI Innovative Drug Industry Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
560900 invests in stocks.